Attached files
file | filename |
---|---|
EX-99.1 - ZIOPHARM ONCOLOGY INC | v210440_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): February 8, 2011
ZIOPHARM
Oncology, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
001-33038
|
84-1475672
|
||
(State
or Other Jurisdiction of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
1180
Avenue of the Americas
19th
Floor
New
York, NY
|
10036
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(646) 214-0700
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
Item
8.01
|
Other
Events.
|
On
February 8, 2011, ZIOPHARM Oncology, Inc. (the “Company”) completed a public
offering of 9,600,000 shares of its common stock. In connection with
the closing, Barclays Capital Inc., the sole book-running manager for the
offering, exercised in full its option to purchase an additional 1,440,000
shares, resulting in ZIOPHARM issuing a total of 11,040,000 shares at the
closing. The net proceeds from the offering were approximately $59.4 million
after deducting underwriting discounts and estimated offering
expenses.
On
February 8, 2011, the Company issued a press release announcing the completion
of the offering and the underwriter’s full exercise of its option to purchase
additional shares. The press release is attached as Exhibit
99.1.
Item
9.01
|
Financial Statements and
Exhibits.
|
(d)
|
Exhibits
|
Exhibit
No.
|
Description
|
99.1
|
Press
release dated February 8, 2011
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ZIOPHARM
Oncology, Inc.
|
|||
Date:
February 8, 2011
|
By:
|
/s/ Richard Bagley | |
Name:
Richard Bagley
|
|||
Title:
President, Chief Operating Officer and Chief Financial
Officer
|
|||
INDEX OF
EXHIBITS
Exhibit No.
|
Description
|
|
99.1
|
Press
release dated February 8, 2011
|